MedPath
Found 59 clinical trials|View Analysis
Sort by:

Molecular Analysis of Gastric and OEsophageal Cancers STudy

Not yet recruiting
Conditions
Adenocarcinoma Esophagus
Adenocarcinoma of the Stomach
Adenocarcinoma - GEJ
Squamous Cell Car. - Esophagus
First Posted Date
2024-11-25
Last Posted Date
2024-11-25
Lead Sponsor
Royal Marsden NHS Foundation Trust
Target Recruit Count
300
Registration Number
NCT06702384
Locations
🇬🇧

Royal Marsden NHS Foundation Trust - Sutton, Surrey, Sutton, Surrey, United Kingdom

🇬🇧

Royal Marsden NHS Foundation Trust - London, London, United Kingdom

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2
Not yet recruiting
Conditions
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
Drug: Camrelizumab
Drug: Apatinib
Drug: S-1, Oxaliplatin
First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Ruijin Hospital
Target Recruit Count
80
Registration Number
NCT06693128
Locations
🇨🇳

Sichuan Cancer Hospital & Institute, Chengdu, China

🇨🇳

Changhai Hospital, Shanghai, China

🇨🇳

Yantai Yuhuangding Hospital, Yantai, China

Pan-tumor MRD Study

Not yet recruiting
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Esophageal Cancer
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Melanoma (Skin Cancer)
NSCLC (Non-small Cell Lung Cancer)
Pancreatic (Exocrine Only)
Mix of Solid Tumors (MOST)
Interventions
Other: blood and tissue samples
First Posted Date
2024-09-20
Last Posted Date
2024-09-20
Lead Sponsor
Flatiron Health
Target Recruit Count
1350
Registration Number
NCT06605404

A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Phase 1
Not yet recruiting
Conditions
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
First Posted Date
2024-09-06
Last Posted Date
2024-09-06
Lead Sponsor
Akeso
Target Recruit Count
294
Registration Number
NCT06586294
Locations
🇨🇳

Zhejiang Cancer Hospital, Hanzhou, Zhejiang, China

Efficacy and Safety of Anti-PD-1, Thymosin, and SOX in Neoadjuvant Treatment of cStage III Gastric/GEJ Adenocarcinoma

Phase 2
Not yet recruiting
Conditions
Gastric Cancer
Esophagogastric Junction Adenocarcinoma
Interventions
Drug: Anti-PD-1 Combined with Thymosin and SOX
First Posted Date
2024-06-17
Last Posted Date
2024-06-17
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
30
Registration Number
NCT06461910

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Not yet recruiting
Conditions
Gastric Cancer
Interventions
Drug: PD-1inhibitor
First Posted Date
2024-05-16
Last Posted Date
2024-05-16
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
60
Registration Number
NCT06417892

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Phase 2
Terminated
Conditions
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Interventions
First Posted Date
2024-01-16
Last Posted Date
2024-08-14
Lead Sponsor
LianBio LLC
Target Recruit Count
6
Registration Number
NCT06206278
Locations
🇨🇳

Anhui Provincial Cancer Hospital, Hefei, Anhui, China

🇨🇳

The Second Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

The Second Hospital Lanzhou University, Lanzhou, Gansu, China

and more 27 locations

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Phase 3
Recruiting
Conditions
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2024-01-16
Last Posted Date
2024-03-25
Lead Sponsor
AskGene Pharma, Inc.
Target Recruit Count
780
Registration Number
NCT06206733
Locations
🇨🇳

Beijing cancer hospital, Beijing, China

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3
Recruiting
Conditions
Locally Advanced Unresectable or Metastatic Gastric Cancer
Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
Drug: M108 monoclonal antibody
Drug: Placebo
Drug: Oxaliplatin
Drug: Capecitabine
First Posted Date
2023-12-20
Last Posted Date
2024-02-28
Lead Sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Target Recruit Count
486
Registration Number
NCT06177041
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath